PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.15 and traded as high as $0.16. PURE Bioscience shares last traded at $0.16, with a volume of 28,193 shares traded.
PURE Bioscience Stock Up 20.7 %
The firm's 50 day simple moving average is $0.13 and its 200-day simple moving average is $0.15. The company has a market capitalization of $17.81 million, a PE ratio of -4.00 and a beta of 0.21.
Get
PURE Bioscience alerts:
Institutional Inflows and Outflows
An institutional investor recently bought a new position in PURE Bioscience stock. IFG Advisory LLC bought a new stake in PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 809,809 shares of the company's stock, valued at approximately $161,000. IFG Advisory LLC owned 0.92% of PURE Bioscience at the end of the most recent quarter. Institutional investors own 0.92% of the company's stock.
PURE Bioscience Company Profile
(Get Rating)
PURE Bioscience, Inc engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in Rancho Cucamonga, CA.
Featured Articles
- Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
Pure Bioscience，Inc.(场外交易市场代码：Pure-Get Rating)的股价在周二的交易中突破了200日移动均线。该股的200日移动均线切入位为0.15美元，最高交易价格为0.16美元。Pure Bioscience股票最新报0.16美元，成交量为28,193股。
纯生物科学类股上涨20.7%
该公司的50日简单移动均线切入位为0.13美元，200日简单移动均线切入位为0.15美元。该公司市值为1,781万美元，市盈率为-4.00，贝塔系数为0.21。
到达
纯生物科学警报：
机构资金流入和流出
一家机构投资者最近买入了一只新的纯生物科学股票头寸。根据IFG Consulting LLC最近提交给美国证券交易委员会(Securities&Exchange Commission)的13F文件，该公司在第三季度购买了Pure Bioscience，Inc.(OTCMKTS：Pure-Get Rating)的新股份。该机构投资者买入了809,809股该公司股票，价值约161,000美元。截至最近一个季度末，IFG Consulting LLC拥有Pure Bioscience 0.92%的股份。机构投资者持有该公司0.92%的股票。
Pure Bioscience公司简介
(获取评级)
Pure Bioscience，Inc.致力于发现、开发和商业化用于病原体和卫生控制的专有抗菌产品。它提供以柠檬酸二氢银为基础的消毒和消毒产品。该公司由Michael L.Krall于1992年8月24日创立，总部设在加利福尼亚州的兰乔库卡蒙加。
专题文章
- 免费获取StockNews.com关于纯生物科学的研究报告(PURE)
- 在盈利井喷之后，Ciena股票是买入机会吗？
- 这就是为什么维京治疗公司在肥胖药物数据上上涨了50%以上
- Meta突破A基点，看起来又成了成长股
- 麦考密克公司的底线已经到了
- 沃尔格林靴子联盟：蓝筹股，高收益扭亏为盈
获得《纯生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pure Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。
